Company Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers.
It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody.
In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer.
It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases.
Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Mar 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 627 |
| CEO | Terry Rosen |
Contact Details
Address: 3928 Point Eden Way Hayward, California 94545 United States | |
| Phone | 510 694 6200 |
| Website | arcusbio.com |
Stock Details
| Ticker Symbol | RCUS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001724521 |
| CUSIP Number | 03969F109 |
| ISIN Number | US03969F1093 |
| Employer ID | 47-3898435 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder and President |
| Robert C. Goeltz II | Principal Financial Officer and Chief Financial Officer |
| Jennifer A. Jarrett M.B.A. | Chief Operating Officer |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Alexander Azoy CPA | Vice President of Finance and Principal Accounting Officer |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Pia Eaves | Vice President of Investor Relations and Strategy |
| Carolyn C. Tang J.D. | General Counsel and Corporate Secretary |
| Holli Kolkey | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2025 | SCHEDULE 13D/A | Filing |
| Feb 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 20, 2025 | SCHEDULE 13D/A | Filing |
| Feb 19, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 424B5 | Filing |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 6, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |